Over the course of the forecast period, the main market players are anticipated to increase their research and development efforts in order to produce medications for irritable bowel syndrome. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions.
The global Irritable Bowel Syndrome Treatment Market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).
Leading Companies in the Irritable Bowel Syndrome Treatment Industry:
1. Abbott
Abbott is a global healthcare leader in medical products and devices manufacturing. It serves people in more than 160 countries. Abbott was established in 1888. Abbott launched its Navitor its latest generation transcatheter aortic valve implantation (TAVI) system to treat Aortic Stenosis in India.
2. Synergy Pharma
Synergy Pharma is a speciality pharmaceuticals company that deals with medical devices, prescription strength vitamins since 2009. The headquarters of Synergy Pharma are situated in Dubai, UAE.
3. Mallinckrodt
Three brothers in 1867 established Mallinckrodt. The headquarters are situated in Dublin, Ireland. Received FDA approval for Terlivaz (terlipressin) for injection, the first and only FDA-approved treatment for adults with hepatorenal syndrome (HRS) involving rapid reduction in Kidney function in 2022.